Search
Landiolol
go.drugbank.com/drugs/DB12212ApprovedInvestigationalfor β-1 adrenergic receptors over β-2 receptors. … Landiolol is a rapid-acting beta (β)-1 adrenergic receptor blocker that blocks the positive chronotropic effect of the beta-1 selective agonist norepinephrine.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-(4-{(2S)-2-hydroxy-3-[{2-[(morpholin-4-ylcarbonyl)amino]ethyl}amino]propoxy}phenyl)propanoate, Benzenepropanoic acid, 4-[(2S)-2-hydroxy-3-[[2-[(4-morpholinylcarbonyl)amino]ethyl]amino]propoxy]-, [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl esterMotolimod
go.drugbank.com/drugs/DB12303InvestigationalMotolimod has been used in trials studying the treatment of Lymphoma, Tongue Cancer, Ovarian Cancer, Adult Solid Neoplasm, and Fallopian Tube Cancer, among others.
Synonyms: {2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl](3H-benzo[f]azepin-4-yl)}-N,N-dipropycarboxamideCategories: Heterocyclic Compounds, 2-Ring, Toll-Like Receptor 8, agonistsRadezolid
go.drugbank.com/drugs/DB12339InvestigationalRadezolid has been used in trials studying the treatment of Abscess, Bacterial Skin Diseases, Streptococcal Infections, Infectious Skin Diseases, and Staphylococcal Skin Infections, among others.
Categories: Heterocyclic Compounds, 1-RingTemocillin
go.drugbank.com/drugs/DB12343ApprovedInvestigationalWithdrawnTemocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.
Categories: Heterocyclic Compounds, 2-RingSiponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigational[L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA … Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS).
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexOmadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent
Categories: P-glycoprotein substratesBelotecan
go.drugbank.com/drugs/DB12459InvestigationalBelotecan has been investigated for the treatment of Epithelial Ovarian Cancer.
Categories: Topoisomerase I Inhibitors, Topoisomerase 1 (TOP1) inhibitorsIbrexafungerp
go.drugbank.com/drugs/DB12471ApprovedIbrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast … [A235414,L34349] Ibrexafungerp was granted FDA approval on 1 June 2021.[L34349]
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: (1S,4AR,6AS,7R,8R,10AR,10BR,12AR,14R,15R)-15-((2R)- 2-AMINO-2,3,3-TRIMETHYLBUTOXY)-1,6A,8,10A-TETRAMETHYL-8- ((2R)-3-METHYLBUTAN-2-YL)-14-(5-(PYRIDIN-4-YL)-1H-1,2,4- TRIAZOL-1-YL)-1,6,6A,7,8,9,10,10A,10B, enfumafungin derivative B-(1,3)-D-glucan synthestis inhibitorAcotiamide
go.drugbank.com/drugs/DB12482InvestigationalAcotiamide has been used in trials studying the treatment of Dyspepsia and Functional Dyspepsia.
Categories: Heterocyclic Compounds, 1-RingMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigational[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1. … 3 prior systemic treatment regimens.
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates